Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? An Antagonist View From the HOPE-3 Trial (Heart Outcomes Evaluation-3).
From the Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (E.M.L., S.Y.). eva.lonn@phri.ca.
Eva M
EM
Lonn
From the Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (E.M.L., S.Y.).
Salim
S
Yusuf
D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054058:Acute Coronary Syndrome / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D001794:Blood Pressure; D048909:Diabetes Complications / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D018572:Disease-Free Survival; D006973:Hypertension / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D051436:Renal Insufficiency, Chronic / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D012307:Risk Factors; D020521:Stroke / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D015996:Survival Rate
antihypertensive agent; high blood pressure; hypertension; risk; treatment